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Cardiovascular diseases (CVD) like myocardial infraction (MI) is still becoming the leading cause of morbidity 
and mortality and major problem in our healthcare system. Nowadays, revolution in high-tech medical treatment 
alongside with well-trained staff could decrease adverse event in ST elevation myocardial infarction (STEMI) 
patient. However, in developing country like Indonesia, those still become a challenge. Fibrinolytic therapy is 
still common practice even though primary percutaneous coronary intervention (PPCI) preferred. Intracranial 
bleeding is one of the most unfavorable effect after fibrinolytic therapy. Clinical should aware with clinical 
deterioration. Here we present case series of deadly intracranial haemorrhage in STEMI patient after fibrinolytic 
therapy.  
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INTRODUCTION 
The mortality rate caused by cardiovascular 
diseases are increasing. In Indonesia there is 
significantly rising of cardiovascular mortality’s 
number from 5% in 1975 to 30% in 2004.1 One of 
the highest concerns for mortality indicate among 
cardiologist is Acute Myocardial Infarction (AMI).2 
AMI patient with ST-elevation myocardial infarct 
(STEMI) needed to undergo reperfusion therapy 
immediately. Primary Percutaneous Coronary 
Intervention (PPCI) is the preferred reperfusion in 
patient with STEMI within 12 hours of symptoms 
onset, however this procedure is still difficult due 
lack of skilled support staff, geographic and 
structural differences in medical system like in 
Indonesia.1-3 Data from Jakarta Acute Coronary 
Syndrome (JAC) Registry data based from 2008 – 
2009 shows 654 acute STEMI patient who were 
admitted to the National Cardiovascular Center 
Harapan Kita (NCCHK), Jakarta, Indonesia only 
29% patients undergo PPCI.1 Pharmacotherapy, 
using fibrinolytic therapy especially in early after  
 
Figure 1. ECG Examination 20-08-2019, 05:32 
AM (pre-fibrinolytic)  
 
Figure 2. ECG Examination 20-08-2019, 09.49 
AM (post-fibrinolytic) 
onset of the symptoms offers a reasonable 
therapeutic option and has yielded satisfactory 
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clinical result.2 Fibrinolytic therapy plays an 
important role in the management of Acute 
Myocardial Infarction (AMI) to minimize tissue 
damage and boost survival rates. However, it has a 
significant risk of bleeding complications, including 
hemorrhagic stroke.4,5  
 
CASE 1 
A 65-year-old woman presented to RSUD 
Pasar Rebo emergency room (ER) because of 
migrated chest pain from left chest to the left arm for 
6 hours. The chest pain was not worsened with rest, 
she complained of nausea and had a vomit one time. 
She had a history of controlled hypertension. 
Physical exam in ER revealed blood pressure (BP) 
140/90 mmHg, heart rate (HR) 64 bpm, respiratory 
rate 20 times per minute and body temperature 
36.4OC. A blood test revealed an increase of SGOT 
and troponin I and a decrease of urea blood. 
Electrocardiography showed sinus tachycardia with 
ST-segment elevation in V2 – V6 (Figure 1). Based 
on examination, there is no contraindication for 
fibrinolytic therapy. Streptokinase was 
administrated. After 60 minutes, the chest pain was 
disappeared and no complained, successful 
fibrinolytic was achieved (Figure 1 dan 2). Although 
the patient had paresthesia for 5 minutes during the 
procedure and patient transferred to the ward.  
 Eight hours later, the left hemiparesis still 
persists. Dynamic ST-T changes, bigeminy PVC 
and tachycardia was found (Figure 3-5). CT scan 
was performed and showed hemorrhagic stroke. 
After all of the antithrombotic and anticoagulant 
medication were discontinued, 19 hours and 30 
minutes later, the patient had a loss of 
consciousness and the resuscitation was not 
performed due to requested Do Not Resuscitate 
(DNR). The patient died after 30 minutes 
(Figure 6). 
 
Figure 3. ECG Examination 20-08-2019, 
07.01 PM 
 
Figure 4. ECG Examination 20-08-2019, 
07.02 PM 
 
Figure 5. ECG Examination 21-08-2019, 05.11 AM 
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Figure 6. ECG Examination 21-08-2019, 02.02 PM
 
CASE 2 
A 57-year-old, underweight woman presented 
to the ER with a 7-hour history of left sided chest 
pain, the pain described as tightness sensation in the 
chest, radiating up into her left shoulder and back. 
She had a history of uncontrolled hypertension and 
untreated left sided breast cancer. There is no history 
of diabetes mellitus and stroke. On examination, 
blood pressure was 148/92 mmHg, pulse 70 bpm, 
and normal respiratory rate. The rest of the clinical 
examination was unremarkable. Twelve leads ECG 
showed sinus rhythm with ST elevation in leads V5-
V9 (Figure 7).  
Acute coronary syndrome (posterolateral ST-
elevation MI) was diagnosed and have no 
contraindication for fibrinolytic therapy. The patient 
administered with fibrinolytic (Streptokinase). 
Following fibrinolytic, the chest pain was 
completely subsided and her ST-elevation resolved 
(Figure 8). 
 
Figure 7. Initial ECG Examination 
 
Figure 8. Post Fibrinolytic ECG Examination 
She remained haemodynamically stable 
until 17 hours post fibrinolytic therapy when the 
patient experienced a sudden loss of 
unconsciousness. A brain CT was performed 
and showed intracranial haemorrhage (Figure 
9). She was referred to the neurosurgeon who 
advised conservative management. Heparin, 
aspirin, and clopidogrel were discontinued. 
 
Figure 9. Brain CT 
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DISCUSSION  
Cardiovascular disease is one of the most 
common causes of morbidity and mortality in 
women in the developed countries.6 The 
Framingham Heart Study also shows women aged 
44-64 years old has 8-9 times greater incidence of 
Myocardial Infarction (MI).7 As presented in our 
case series, both patients are woman with age 65 
years old and 57 years old, respectively. 
Thrombolytic therapy for STEMI patient still 
common, even though PCI is preferred. A 
systematic study with total sample size 404,556 
patient shows in STEMI patient regarding treatment, 
71.2% received thrombolytics.4 In our case series, 
STEMI patient treated with pharmacological 
intervention, fibrinolytic therapy, seem reasonable.  
The most serious complications of fibrinolytic 
therapy are death, re-infraction (AMI), and major 
bleeding (MB). The most MB that may be fatal in 
half to two-third of patients is haemorrhagic 
stroke.5,8 Intracranial haemorrhage should be 
suspected in any patient who develops sudden 
neurological deterioration, a decline in the level of 
consciousness, new headache, nausea and vomiting 
or sudden rise in blood pressure (BP) after 
fibrinolytic therapy. Any symptoms which 
previously mention should alert the clinician and 
brain CT should be done to rule this out. The first 24 
hours is the most common time to happened, the 
patient should be monitored closely.8 Similar with 
our patient, neurological deficit happened in both 
patients within 24 hours after thrombolytic therapy. 
We also performed brain CT on both patient and 
intracranial haemorrhage was found.  
 There are four factors that identified as 
independent predictors of intracranial haemorrhage; 
age over 65 years, bodyweight below 70 kg, 
hypertension on hospital admission, and 
administration of alteplase.9 Hypertension is known 
to be a major risk factor for CVD. Study had found 
that the increase of SBP and DBP were associated 
with impaired fibrinolytic potensial.10 In these cases, 
both patients had a history of hypertension, but one 
patient had controlled hypertension and used 
antihypertension medication routinely. Although 
antihypertensive treatment does reduce the risk of 
CVD, the results are usually not commensurate to 
what would be predicted.11 This discrepancy may be 
caused by contributing factors, such as a 
prothrombic state, which is related to blood pressure 
level but is not corrected with antihypertensive 
treatment. Study had found that increased blood 
pressure is associated with decreased fibrinolytic 
potential and increased plasma viscosity supports 




Haemorrhagic stroke is one of the most 
serious and fatal complication during the first 24 
h of fibrinolytic therapy. Clinician should 
follow up patient clinical status and be aware 
with red flag symptoms after fibrinolytic 
therapy. There are several contributed factors, 
hypertension is one of the major risk factors. In 
this case, patient with controlled hypertension 
had a haemorrhagic stroke after fibrinolytic 
treatment, it can be caused by several factors 
such as a prothrombic state, which is related to 
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